Despite the recall of several different manufacturers’ formulations of extended-release (ER) metformin because of higher than acceptable levels of a potentially cancer-causing chemical, experts say patients and providers should experience no significant disruptions in access to therapy, and they urge patients not to switch or discontinue their medication without consulting their doctor.